The role of mesalazine in the treatment of ulcerative colitis Review article
Article Sidebar
Published:
Sep 30, 2021
Keywords:
5-ASA, mesalazine, inflammatory bowel diseases, ulcerative colitis
Main Article Content
Abstract
The article presents data on the mechanism of action of sulfasalazine and 5-ASA preparations. The latest meta-analysis and polish and ECCO recommendations for the treatment of patients with ulcerative colitis are also included.
Article Details
How to Cite
Kaniewska, M., Lewandowski , K., & Rydzewska , G. (2021). The role of mesalazine in the treatment of ulcerative colitis. Medycyna Faktow (J EBM), 14(3(52), 260-266. https://doi.org/10.24292/01.MF.0321.7
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Rydzewska G, Małecka-Panas E (ed). Choroba Leśniowskiego-Crohna – 100 lat diagnostyki i terapii. Wydawnictwo Medyczne Termedia, Poznań 2008.
2. Langholz E, Munkholm P, Davidsen M et al. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology. 1994; 107: 3-11.
3. Rawa T. Doustne preparaty kwasu 5-aminosalicylowego w leczeniu wrzodziejącego zapalenia jelita grubego. Gastroenterol Klin. 2012; 4(3): 98-104.
4. Svartz N. Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Medica Scandinavia. 1942; 110: 557-90.
5. Van Hees PAM, Bakker JH, Tongeren JHM. Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine. Gut. 1980; 21: 632-5.
6. Nielsen OH. Sulfasalazine intolerance: a retrospective study of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982; 17: 389-93.
7. Myers B, Evans DNW, Rhodes J et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987; 28: 196-200.
8. Dubuquoy L, Rosseaux C, Thueru X. PRARg as a new therapeutic target in inflammatory bowel diseases. Gut. 2006; 55: 1341-9.
9. Rousseaux C, Lefebvre B, Dubuquoy L et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med. 2005; 201: 1205-15.
10. Mahida YR, Lamming CE, Gallagher A et al. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 1991; 32: 50-4.
11. Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982; 69: 494-7.
12. Egan LJ, Mays DC, Huntoon CJ et al. Inhibition of interleukin-1-stimulated NF-kappa B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999; 274: 26448-53.
13. Dew MJ, Hughes PJ, Lee MG et al. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982; 14: 405-8.
14. Hanauer S, Sandborn W, Lichtenstein G et al. MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflamm Bowel Dis. 2007; 13(S5): 663.
15. Kamm MA, Sandborn WJ, Gassull M et al. Once-daily, high concentration MMX mesalamine in active ulcerative colitis. Gastroenterol. 2007; 132: 66-75.
16. Meier J, Sturm A. Current treatment of ulcerative colitis. World Gastroenterol. 2011; 17(27): 3204-12. http://doi.org/10.3748/wjg.v17.i27.3204.
17. Rydzewska G. Przestrzeganie zaleceń w chorobach przewlekłych na przykładzie leczenia mesalazyną w nieswoistych zapalnych chorobach jelit. Zakażenia XXI wieku. 2019; 2(1): 1-5. http://doi.org/10.31350/zakazenia/2019/1/Z2019006.
18. Kamm MA, Lichtenstein GR, Sandborn WJ et al. Randomisedtrial, of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008; 57: 893-902.
19. Qiu X, Ma J, Wang K et al. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget. 2017; 8(1): 1031-45. http://doi.org/10.18632/oncotarget.13715.
20. Rydzewska G. Chemoprewencja w nieswoistych chorobach zapalnych jelit. Zakażenia XXI wieku. 2018; 1(1): 11-5.
21. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; 2.
22. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012; 10.
23. Hanauer SB, Sandborn WJ, Kornbluth A et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active disease. Ascend II Trial. Am J Gastroenterol. 2005; 100: 2478-85.
24. Wang Y, Parker CE, Bhanji T et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016; 4: CD00054.
25. Murray A, Nguyen TM, Parker CE et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Meta-Analysis. Cochrane Database Syst Rev. 2020; 8(8): CD000544. http://doi.org/10.1002/14651858.
26. Barberio B, Segal J, Ford A et al. Efficacy of oral, Topical or Combined Oral and Topical 5-ASA in Ulcerative Colitis: Systemic Review and Network Meta-Analysis. J Crohns Colitis. 2021; 15(7): 1184-96.
27. Harbord M, Eliakim R, Bettenworth D et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017; 11(7): 769-84.
28. Torres J, Bonovas S, Doherty G et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020; 14(1): 4-22.
29. Eder P, Łodyga M, Rydzewska G et al. Postępowanie z pacjentem z wrzodziejącym zapaleniem jelita grubego. Prz Gastroenterol. 2013; 8(1): 1-20.
30. Łodyga M, Eder P, Rydzewska G. Wytyczne Grupy Roboczej Konsultanta Krajowego w dziedzinie Gastroenterologii i Polskiego Towarzystwa Gastroenterologii dotyczące postępowania z pacjentem z chorobą Leśniowskiego-Crohna. Prz Gastroenterol. 2012; 7(6): 317-38.
2. Langholz E, Munkholm P, Davidsen M et al. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology. 1994; 107: 3-11.
3. Rawa T. Doustne preparaty kwasu 5-aminosalicylowego w leczeniu wrzodziejącego zapalenia jelita grubego. Gastroenterol Klin. 2012; 4(3): 98-104.
4. Svartz N. Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Medica Scandinavia. 1942; 110: 557-90.
5. Van Hees PAM, Bakker JH, Tongeren JHM. Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine. Gut. 1980; 21: 632-5.
6. Nielsen OH. Sulfasalazine intolerance: a retrospective study of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982; 17: 389-93.
7. Myers B, Evans DNW, Rhodes J et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987; 28: 196-200.
8. Dubuquoy L, Rosseaux C, Thueru X. PRARg as a new therapeutic target in inflammatory bowel diseases. Gut. 2006; 55: 1341-9.
9. Rousseaux C, Lefebvre B, Dubuquoy L et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med. 2005; 201: 1205-15.
10. Mahida YR, Lamming CE, Gallagher A et al. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 1991; 32: 50-4.
11. Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982; 69: 494-7.
12. Egan LJ, Mays DC, Huntoon CJ et al. Inhibition of interleukin-1-stimulated NF-kappa B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999; 274: 26448-53.
13. Dew MJ, Hughes PJ, Lee MG et al. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982; 14: 405-8.
14. Hanauer S, Sandborn W, Lichtenstein G et al. MMX mesalamine for providing remission of active mild-to-moderate ulcerative colitis: an evidence-based medicine analysis. Inflamm Bowel Dis. 2007; 13(S5): 663.
15. Kamm MA, Sandborn WJ, Gassull M et al. Once-daily, high concentration MMX mesalamine in active ulcerative colitis. Gastroenterol. 2007; 132: 66-75.
16. Meier J, Sturm A. Current treatment of ulcerative colitis. World Gastroenterol. 2011; 17(27): 3204-12. http://doi.org/10.3748/wjg.v17.i27.3204.
17. Rydzewska G. Przestrzeganie zaleceń w chorobach przewlekłych na przykładzie leczenia mesalazyną w nieswoistych zapalnych chorobach jelit. Zakażenia XXI wieku. 2019; 2(1): 1-5. http://doi.org/10.31350/zakazenia/2019/1/Z2019006.
18. Kamm MA, Lichtenstein GR, Sandborn WJ et al. Randomisedtrial, of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008; 57: 893-902.
19. Qiu X, Ma J, Wang K et al. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget. 2017; 8(1): 1031-45. http://doi.org/10.18632/oncotarget.13715.
20. Rydzewska G. Chemoprewencja w nieswoistych chorobach zapalnych jelit. Zakażenia XXI wieku. 2018; 1(1): 11-5.
21. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; 2.
22. Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012; 10.
23. Hanauer SB, Sandborn WJ, Kornbluth A et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active disease. Ascend II Trial. Am J Gastroenterol. 2005; 100: 2478-85.
24. Wang Y, Parker CE, Bhanji T et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016; 4: CD00054.
25. Murray A, Nguyen TM, Parker CE et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Meta-Analysis. Cochrane Database Syst Rev. 2020; 8(8): CD000544. http://doi.org/10.1002/14651858.
26. Barberio B, Segal J, Ford A et al. Efficacy of oral, Topical or Combined Oral and Topical 5-ASA in Ulcerative Colitis: Systemic Review and Network Meta-Analysis. J Crohns Colitis. 2021; 15(7): 1184-96.
27. Harbord M, Eliakim R, Bettenworth D et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017; 11(7): 769-84.
28. Torres J, Bonovas S, Doherty G et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020; 14(1): 4-22.
29. Eder P, Łodyga M, Rydzewska G et al. Postępowanie z pacjentem z wrzodziejącym zapaleniem jelita grubego. Prz Gastroenterol. 2013; 8(1): 1-20.
30. Łodyga M, Eder P, Rydzewska G. Wytyczne Grupy Roboczej Konsultanta Krajowego w dziedzinie Gastroenterologii i Polskiego Towarzystwa Gastroenterologii dotyczące postępowania z pacjentem z chorobą Leśniowskiego-Crohna. Prz Gastroenterol. 2012; 7(6): 317-38.